Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + pembrolizumab + TTFields for recurrent glioblastoma
MOH_2023-06-19_012752Phase 2Not yet recruiting
- Sponsor
- פרופ' דבורה בלומנטל
- Start
- May 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and pembrolizumab in glioblastoma (GBM), sponsored by פרופ' דבורה בלומנטל. Primary endpoint: Progression-free survival. Planned start May 2023; status: not yet recruiting.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on MOH_2023-06-19_012752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-19_012752.